Choosing a behavioral therapy platform for pharmacotherapy of substance users

Drug and Alcohol Dependence

Volumn 75, Issue 2, 2004, Pages 123-134

  Carroll, Kathleen M ^a   Kosten, Thomas R ^a   Rounsaville, Bruce J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adherence; Behavioral therapies; Pharmacotherapy trials; Treatment

Indexed keywords

AMFEBUTAMONE; COCAINE; DESIPRAMINE; DISULFIRAM; HEPATITIS B VACCINE; MAZINDOL; METHADONE; NALTREXONE; OPIATE; VACCINE;

ALCOHOLISM; ANALYTICAL ERROR; BEHAVIOR THERAPY; CLINICAL TRIAL; COCAINE DEPENDENCE; COGNITION; DRUG USE; HUMAN; META ANALYSIS; MOTIVATION; PATIENT COMPLIANCE; PATIENT COUNSELING; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; SUBSTANCE ABUSE; TREATMENT OUTCOME;

BEHAVIOR THERAPY; HUMANS; SUBSTANCE-RELATED DISORDERS;

EID: 3242753530     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2004.02.007     Document Type: Review

References (114)

1. Aharonovich E., Nunes E.V., Hasin D. Cognitive impairment, retention and abstinence among cocaine abusers in cognitive-behavioral treatment. Drug Alcohol Depend. 71:2003;207-211
2. Alterman A.I., Kampman K.M., Boardman C., Cacciola J.S., Rutherford M.J., McKay J.R., Maany I. A cocaine-positive baseline urine predicts outpatient treatment attrition and failure to attain initial abstinence. Drug Alcohol Depend. 46:1997;79-85
3. Annis, H.M., Davis, C.S. Relapse prevention. In: Hester, R.K., Miller, W.R. (Eds.), 1989. Handbook of Alcoholism Treatment Approaches, Pergamon Press, New York, pp. 170-182.
4. Anton R.F., Moak D.H., Waid L.R., Latham P.K., Malcolm R.J., Dias J.K. Naltrexone and cognitive-behavioral therapy for the treatment of outpatient alcoholics: Results of a placebo-controlled trial. Am. J. Psychiatry. 156:1999;1758-1764
5. Babor T.F. Avoiding the horrid and beastly sin of drunkenness: Does dissuasion make a difference. J. Consult. Clin. Psychol. 62:1994;1127-1140
6. Best, S.E., Malison, R.T., Wallace, E.A., Zoghbi, S.S., Zea-Ponce, Y., Baldwin, R.M., Innis, R.B., Kosten, T.R., 1994. SPECT imaging of the dopamine transporter in cocaine abstinence: preliminary studies using [123-I]b-CIT. In: Harris, L.S. (Ed.), Problems of Drug Dependence, 1994, National Institute on Drug Abuse Research Monograph 153, NIDA, Washington, DC.
7. Bien T.H., Miller W.R., Tonigan J.S. Brief interventions for alcohol problems: a review. Addiction. 88:1993;315-335
8. Brown R.A., Evans D.M., Miller I.W., Burgess E.S., Mueller T.I. Cognitive-behavioral treatment for depression in alcoholism. J. Consult. Clin. Psychol. 65:1997;715-726
9. Carroll, K.M., 1998. A cognitive-behavioral approach: treating cocaine addiction. In: Therapy Manuals for Drug Addiction, NIDA, Rockville, Maryland.
10. Carroll K.M. Manual guided psychosocial treatment: a new virtual requirement for pharmacotherapy trials. Arch. Gen. Psychiatry. 54:1998;923-928
11. Carroll K.M., Ball S.A., Nich C., O'Connor P.G., Eagan D., Frankforter T.L., Triffleman E.G., Shi J., Rounsaville B.J. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: Efficacy of contingency management and significant other involvement. Arch. Gen. Psychiatry. 58:2001;755-761
12. Carroll, K.M., Fenton, L.R., Ball, S.A., Nich, C., Frankforter, T.L., Shi, J., Rounsaville, B.J., 2004. Efficacy of disulfiram and cognitive-behavioral therapy in cocaine-dependent outpatients. A randomized placebo-controlled trial. Arch. Gen. Psychiatry 61, 264-272.
13. Carroll K.M., Nich C., Ball S.A., McCance-Katz E., Rounsaville B.J. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction. 93:1998a;713-728
14. Carroll K.M., Nich C., Ball S.A., McCance-Katz E.F., Frankforter T.F., Rounsaville B.J. One year follow-up of disulfiram and psychotherapy for cocaine-alcohol abusers: Sustained effects of treatment. Addiction. 95:2000;1335-1349
15. Carroll, K.M., Nuro, K.F., Rounsaville, B.J., Petrakis, I., 1998b. Compliance Enhancement: A Clinician's Manual for Pharmacotherapy Trials in the Addictions: Unpublished manual: Yale University Psychotherapy Development Center.
16. Carroll K.M., Rounsaville B.J., Gordon L.T., Nich C., Jatlow P.M., Bisighini R.M., Gawin F.H. Psychotherapy and pharmacotherapy for ambulatory cocaine abusers. Arch. Gen. Psychiatry. 51:1994a;177-197
17. Carroll K.M., Rounsaville B.J., Nich C., Gordon L.T., Wirtz P.W., Gawin F.H. One year follow-up of psychotherapy and pharmacotherapy for cocaine dependence: delayed emergence of psychotherapy effects. Arch. Gen. Psychiatry. 51:1994;989-997
18. Chick J., Gough K., Falkowski W., Kershaw P., Hore B., Mehta B., Ritson B., Ropner R., Torley D. Disulfiram treatment of alcoholism. Br. J. Psychiatry. 161:1992;84-89
19. Covey L.S., Glassman A.H., Stetner F., Rivelli S., Stage K. A randomized trial of sertraline as a cessation aid for smokers with a history of major depression. Am. J. Psychiatry. 159:2002;1731-1737
20. Crits-Christoph P., Siqueland L., Blaine J.D., Frank A., Luborsky L., Onken L.S., Muenz L., Thase M.E., Weiss R.D., Gastfriend D.R., Woody G., Barber J.P., Butler S., Dale D., Salloum I., Bishop S., Najavits L., Lis J. Psychosocial treatments for cocaine dependence: results of the National Institute on drug abuse collaborative cocaine study. Arch. Gen. Psychiatry. 56:1999;495-502
21. Daley, D.C., Mercer, D., Carpenter, G., 2002. Drug Counseling for Cocaine Addiction: The Collaborative Cocaine Treatment Study Model. Therapy Manuals for Drug Addiction, NIDA, Bethesda, MD.
22. de Lima M.S., de Oliveira Soares B.G., Reisser A.A., Farrell M. Pharmacological treatment of cocaine dependence: a systematic review. Addiction. 97:2002;931-949
23. DeRubeis R.J., Crits-Christoph P. Empirically supported individual and group psychological treatments for adult mental disorders. J. Consult. Clin. Psychol. 66:1998;37-52
24. Dunn C., Deroo I., Rivara F.P. The use of brief interventions adapted from motivational interviewing across behavioral domains: a systematic review. Addiction. 96:2001;1725-1742
25. Fals-Stewart W., O'Farrell T.J., Birchler G.R. Behavioral couples therapy for male substance-abusing patients: A cost outcomes analysis. J. Consult. Clin. Psychol. 65:1997;789-802
26. Fawcett J., Epstein P., Fiester S.J., Elkin I., Autry J.H. Clinical management-imipramine/placebo administration manual: NIMH treatment of depression collaborative research program. Psychopharmacol. Bull. 23:1987;309-324
27. Feinstein, A.R., 1979. Compliance bias and the interpretation of therapeutic trials. In: Haynes, R.B., Taylor, D.W., Sackett, D.L. (Eds.), Compliance in Healthcare, Johns Hopkins Press, Baltimore, MD, pp. 309-322.
28. Freedman B. Equipoise and the ethics of clinical research. N. Engl. J. Med. 317:1987;141-145
29. Fudala, P.J., Bridge, T.P., Herbert, S., Williford, W.O., Chiange, C.N., Jones, K., Collins, J.F., Raisch, D., Casadonte, P., Goldsmith, R.J., Ling, W., Malkerneker, U., McNicholas, L., Renner, J., Stine, S., Tusel, D.J., for the Buprenorphine/Naloxone Collaborative Study Group (2003) Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N. Engl. J. Med., 329 949-958.
30. Fuller R.K., Branchey L., Brightwell D.R., Derman R.M., Emrick C.D., Iber F.L., James K.E., Lacoursiere R.B., Lee K.K., Lowenstam I. Disulfiram treatment of alcoholism: a Veterans Administration cooperative study. JAMA. 256:1986;1449-1455
31. George T.P., Ziedonis D.M., Feingold A., Pepper W.T., Satterburg C.A., Winkel J., Rounsaville B.J., Kosten T.R. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenica. Am. J. Psychiatry. 157:2000;1835-1842
32. Griffith J.D., Rowan-Szal G.A., Roark R.R., Simpson D.D. Contingency management in outpatient methadone treatment: a meta-analysis. Drug Alcohol Depend. 58:2000;55-66
33. Hall S.M., Humfleet G.L., Reus V.I., Munoz R.F., Hartz D.T., Maude-Griffin P.M. Psychological intervention and antidepressant treatment in smoking cessation. Arch. Gen. Psychiatry. 59:2002;930-936
34. Hall S.M., Reus V.I., Munoz R.F., Sees K.L., Humfleet G., Hartz D.T., Frederick S., Triffleman E.G. Nortripyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch. Gen. Psychiatry. 55:1998;683-690
35. Heinala P., Alho H., Kiianmaa K., Lonnqvist J., Kuoppalalmi K., Sinclair J.D. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double blind, placebo controlled trial. J. Consult. Clin. Psychol. 21:2001;287-292
36. Henggeler S.W., Melton G.B., Brondino M.J., Scherer D.G., Hanley J.H. Multisystemic therapy with violent and chronic juvenile offenders and their families: the role of treatment fidelity. J. Consult. Clin. Psychol. 65:1997;821-833
37. Higgins S.T., Badger G.J., Budney A.J. Initial abstinence and success in achieving longer term cocaine abstinence. Exp. Clin. Psychopharmacol. 8:2000a;377-386
38. Higgins S.T., Budney A.J., Bickel W.K., Foerg F.E., Donham R., Badger G.J. Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch. Gen. Psychiatry. 51:1994;568-576
39. Higgins S.T., Budney A.J., Bickel W.K., Hughes J.R. Achieving cocaine abstinence with a behavioral approach. Am. J. Psychiatry. 150:1993;763-769
40. Higgins S.T., Delany D.D., Budney A.J., Bickel W.K., Hughes J.R., Foerg F., Fenwick J.W. A behavioral approach to achieving initial cocaine abstinence. Am. J. Psychiatry. 148:1991;1218-1224
41. Higgins S.T., Wong C.J., Badger G.J., Haug-Ogden D.E., Dantona R.L. Contingent reinforcement increases cocaine abstinence during outpatient treatment and one year follow-up. J. Consult. Clin. Psychol. 68:2000;64-72
42. Huey S.J., Hennegler S.W., Brondino M.J., Pickrel S.G. Mechanisms of change in multisystemic therapy: reducing delinquent behavior through therapist adherence and improved family and peer functioning. J. Consult. Clin. Psychol. 68:2000;451-467
43. Irvin J.E., Bowers C.A., Dunn M.E., Wong M.C. Efficacy of relapse prevention: a meta-analytic review. J. Consult. Clin. Psychol. 67:1999;563-570
44. Kadden, R., Carroll, K.M., Donovan, D., Cooney, J.L., Monti, P., Abrams, D., Litt, M., Hester, R.K., 1992. Cognitive-behavioral Coping Skills Therapy Manual: A Clinical Research Guide for Therapists Treating Individuals with Alcohol Abuse and Dependence Project MATCH Monograph Series, vol. 3, NIAAA, Rockville, MD.
45. Kampman, K.M., Alterman, A.I., Volpicelli, J.R., Maany, I., Muller, E.S., Luce, D.L., Mulholland, E.M., Jawad, A.F., Parikh, G.A., Mulvaney, F.D., Weinrieb, R.M., O'Brien, C.P., 2001. Cocaine withdrawal symptoms and initial urine toxicology results predict treatment attrition in outpatient dependence treatment. Psychol. Addict. Behav. 15, 52-59.
46. Kosten T.R., Biegel D. Therapeutic vaccines for substance dependence. Expert Rev. Vaccines. 1:2002a;363-371
47. Kosten, T.R., Oliveto, A., Feingold, A., Poling, J., Sevarino, K., McCance-Katz, E., Stine, S, Gonzalez, G., Gonsai, K., 2004. Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend. 70, 315-328.
48. Kosten T.R., Rosen M.I., Bond I., Settles M., Roberts J.S., Shields J., Jack L., Fox B. Human therapeutic cocaine vaccine: Safety and immunogenicity. Vaccine. 20:2002b;1196-1204
49. Krystal, J.H., Cramer, J.A., Krol, W.F., Kirk, G.F., Rosenheck, R.A., for the Naltrexone Cooperative Study 425 Group, 2001. Naltrexone in the treatment of alcohol dependence. N. Engl. J. Med. 345 1734-1739.
50. Lavori P.W. Clinical trials in psychiatry: should protocol deviation censor patient data. Neuropsychopharmacology. 6:1992;39-48
51. Leshner A.I. Science-based views of drug addiction and its treatment. JAMA. 282:1999;1314-1316
52. Levine R.J. The use of placebos in randomized clinical trials. IRB: Rev. Hum. Subj. Res. 7:1985;1-4
53. Little K.Y., Zhang L., Desmond T., Frey K.A., Dalack G.W., Cassin B.J. Striatal dopaminergic abnormalities in human cocaine users. Am. J. Psychiatry. 156:1999;238-245
54. Malison R.T., Best S.E., van Dyck C.H., McCance-Katz E.F., Wallace E.A., Laruelle M., Baldwin R.M., Seibyl J.P., Price L.H., Kosten T.R., Innis R.B. Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [123I]-CIT SPECT. Am. J. Psychiatry. 155:1998;832-834
55. Margolin A., Avants S.K., Malison R.T., Kosten T.R. High- and low-dose mazindol for cocaine dependence in methadone-maintained patients: a preliminary evaluation. Subst. Abus. 18:1997;125-131
56. Marlatt, G.A., Gordon, J.R., 1985. Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviors, Guilford Press, New York.
57. Mason B.J., Salvato F.R., Williams L.D., Ritvo E.C., Cutler R.B. A double-blind, placebo controlled study of oral nalmefene for alcohol dependence. Arch. Gen. Psychiatry. 56:1999;719-724
58. McDowell D.M., Levin F.R., Seracini A.M., Nunes E.V. Venlafaxine treatment of cocaine abusers with depressive disorders. Am. J. Drug Alcohol Abuse. 26:2000;25-31
59. McLellan A.T., Arndt I.O., Metzger D., Woody G.E., O'Brien C.P. The effects of psychosocial services in substance abuse treatment. JAMA. 269:1993;1953-1959
60. Mercer, D.E., Woody, G.E., 1999. An Individual Drug Counseling Approach to Treat Cocaine Addiction: The Collaborative Cocaine Treatment Study Model, NIDA, Rockville, MD.
61. Miller F.G. Placebo controlled trials in psychiatric research: An ethical perspective. Biol. Psychiatry. 47:2000a;707-716
62. Miller F.G., Brody H. What makes placebo controlled trials unethical. Am. J. Bioeth. 2:2002a;3-9
63. Miller W.R. Rediscovering fire: Small interventions, large effects. Psychol. Addict. Behav. 14:2000b;6-18
64. Miller W.R., Mount K.A. A small study of training in motivational interviewing: Does one workshop change clinician and client behavior. Behav. Cogn. Psychother. 29:2001;457-471
65. Miller, W.R., Rollnick, S., 2002b. Motivational Interviewing: Preparing People for Change, second ed., Guilford Press, New York.
66. Miller W.R., Wilbourne P.L. Mesa Grande: a methodological analysis of clinical trials of treatments for alcohol use disorders. Addiction. 97:2002c;265-277
67. Modesto-Lowe V., Van Kirk J. Clinical uses of naltrexone: a review of the evidence. Exp. Clin. Psychopharmacol. 10:2002;213-227
68. Monti, P.M., Rohsenow, D.J., Abrams, D.B., Zwick, W.R., Binkoff, J.A., Munroe, S.M., Fingeret, A.L., Nirenberg, T.D., Liepman, M.R., Pedrasa, M., Kadden, R.M., Cooney, J.L., 1989. Treating Alcohol Dependence: A Coping Skills Training Guide in the Treatment of Alcoholism, Guilford Press, New York.
69. Morgenstern J., Longabaugh R. Cognitive-behavioral treatment for alcohol dependence: A review of the evidence for its hypothesized mechanisms of action. Addiction. 95:2000;1475-1490
70. Morgenstern J., Morgan T.J., McCrady B.S., Keller D.S., Carroll K.M. Manual-guided cognitive behavioral therapy training: A promising method for disseminating empirically supported substance abuse treatments to the practice community. Psychol. Addict. Behav. 15:2001;83-88
71. Mulvaney F.D., Alterman A.I., Boardman C.R., Kampman K.M. Severity of cocaine use and prediction of treatment attrition. J. Subst. Abus. Treat. 16:1999;129-135
72. National Institute on Drug Abuse, 2000. Principles of Drug Abuse Treatment: A Research-Based Guide, NIDA, Bethesda, Maryland.
73. Nowinski, J., Baker, S., Carroll, K.M., 1992. Twelve-Step Facilitation Therapy Manual: A Clinical Research Guide for Therapists Treating Individuals with Alcohol Abuse and Dependence. In: Project MATCH Monograph Series, vol. 1, NIAAA, Rockville, MD.
74. Nunes E.V., Quitkin F.M., Donovan S.J., Deliyannides D., Ocepek-Welikson K., Koenig T., Brady R., McGrath P.J., Woody G.E. Imipramine treatment of opiate dependent patients with depressive disorders: A placebo-controlled trial. Arch. Gen. Psychiatry. 55:1998;153-160
75. O'Brien C.P. A range of research-based pharmacotherapies for addiction. Science. 278:1997;66-70
76. O'Farrell T.J., Cutter H.S., Choquette K.A., Floyd F.J. Behavioral marital therapy for male alcoholics: Marital and drinking adjustment during two years after treatment. Behav. Ther. 23:1992a;529-549
77. O'Farrell T.J., Litten R.Z. Techniques to enhance compliance with disulfiram. Alcohol Clin. Exp. Res. 16:1992;1035-1041
78. O'Malley S.S., Jaffe A.J., Chang G., Rode S., Schottenfeld R., Meyer R.E., Rounsaville B.J. Six month follow-up of naltrexone and psychotherapy for alcohol dependence. Arch. Gen. Psychiatry. 53:1996;217-224
79. O'Malley S.S., Jaffe A.J., Chang G., Schottenfeld R., Meyer R.E., Rounsaville B.J. Naltrexone and coping skills therapy for alcohol dependence: A controlled study. Arch. Gen. Psychiatry. 49:1992;881-887
80. O'Malley S.S., Rounsaville B.J., Farren C., Namkoong K., Wu R., Robinson J., O'Connor P.G. Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs. specialty care: a nested sequence of three randomized trials. Arch. Int. Med. 163:2003;1695-1704
81. Owens S.M. Antibodies as pharmacokinetic and metabolic modifiers of neurotoxicity. NIDA Res. Monogr. Ser. 173:1997;259-272
82. Patten C.A., Martin J.E., Myers M.G., Calfas K.J., Williams C.D. Effectiveness of cognitive-behavioral therapy for smokers with histories of alcohol dependence and depression. J. Stud. Alcohol. 59:1998;327-335
83. Petrakis I., Carroll K.M., Gordon L.T., Nich C., Kosten T.R., Rounsaville B.J. Fluoxetine treatment of depressive disorders in methadone maintained opioid addicts. Drug Alcohol Depend. 50:1998;221-226
84. Petry N.M. A comprehensive guide to the application of contigency management procedures in clinical settings. Drug Alcohol Depend. 58:2000;9-25
85. Petry N.M., Martin B. Low-cost contingency management for treating cocaine- and opioid abusing methadone patients. J. Consult. Clin. Psychol. 70:2002;398-405
86. Petry N.M., Martin B., Cooney J.L., Kranzler H.R. Give them prizes and they will come: Contingency management treatment of alcohol dependence. J. Consult. Clin. Psychol. 68:2000;250-257
87. Petry N.M., Petrakis I., Trevisan L., Wiredu L., Boutros N., Martin B., Kosten T.R. Contingency management interventions: From research to practice. Am. J. Psychiatry. 20:2001;33-44
88. Pettinati H.M., Volpicelli J.R., Pierce J.D., O'Brien C.P. Improving naltrexone response: An intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. J. Addict. Dis. 19:2000;71-83
89. Pettinati, H.M., Weiss, R.D., Miller, W.R., Donovan, D., Rounsaville, B.J., in press. Medical Management (MM) Treatment Manual: A Guide for Medically-Trained Clinicians Providing Pharmacotherapy as Part of the Treatment of Alcohol Dependence, NIAAA, Bethesda, MD.
90. Preston K.L., Silverman K., Umbricht A., DeJesus A., Montoya I.D., Schuster C.R. Improvement in naltrexone treatment compliance with contingency management. Drug Alcohol Depend. 54:1999;127-135
91. Project MATCH Research Group (1997) Matching Alcohol Treatments to Client Heterogeneity: Project MATCH posttreatment drinking outcomes. J. Stud. Alcohol, 58, 7-29.
92. Rawson R.A., Huber A., McCann M.J., Shoptaw S., Farabee D., Reiber C., Ling W. A comparison of contingency management and cognitive-behavioral approaches during methadone maintenance for cocaine dependence. Arch. Gen. Psychiatry. 59:2002;817-824
93. Rawson R.A., Shoptaw S.J., Obert J.L., McCann M.J., Hasson A.L., Marinelli Casey P.J., Brethen P.R., Ling W. An intensive outpatient approach for cocaine abuse treatment: The Matrix model. J. Subst. Abus. Treat. 12:1995;117-127
94. Rigsby M.O., Rosen M.I., Beauvais J., Cramer J.A., Rainey P.M., O'Malley S.S., Dieckhaus K.D., Rounsaville B.J. Cue dose training with monetary reinforcement: Pilot study of an antiretroviral adherence intervention. J. Gen. Int. Med. 15:2000;841-847
95. Rohsenow D.J., Colby S.M., Monti P.M., Swift R.M., Martin R.A., Mueller T.I., Gordon A., Eaton C.A. Predictors of compliance with naltrexone among alcoholics. Alcohol. Clin. Exp. Res. 24:2000;1542-1549
96. Rounsaville, B.J., 1995. Can psychotherapy rescue naltrexone treatment of opioid addiction? In: Onken, L.S., Blaine, J.D., (Eds.), Potentiating the Efficacy of Medications: Integrating Psychosocial Therapies with Pharmacotherapies in the Treatment of Drug Dependence, NIDA, Rockville, MD, pp. 37-52.
97. Rubel E.C., Sobell L.C., Miller W.R. Do continuing workshops improve participants skills? Effects of a motivational interviewing workshop on substance-abuse counselors' skills and knowledge. Behav. Ther. 23:2000;73-77
98. Rychtarik R.G., Connors G.J., Derman K.H., Stasiewicz P.R. Alcoholics Anonymous and the use of medications to prevent relapse: An anonymous survey of member attitudes. J. Stud. Alcohol. 61:2000;134-138
99. Schmitz J.M., Averill P., Stotts A.L., Moeller F.G., Rhoades H.M., Grabowski J. Fluoxetine treatment of cocaine-dependent patients with major depressive disorder. Drug Alcohol Depend. 63:2001a;207-214
100. Schmitz J.M., Stotts A.L., Rhoades H.M., Grabowski J. Naltrexone and relapse prevention for cocaine-dependent patients. Addict. Behav. 26:2001b;167-180
101. Seal K.H., Kral A.H., Lorvick J., McNees A., Gee L., Edlin B.R. A randomized controlled trial of monetary incentives vs. outreach to enhance adherence to the hepatitis B vaccine series among injection drug users. Drug Alcohol Depend. 71:2003;127-131
102. Sholomskas, D., Syracuse, G., Rounsaville, B.J., Carroll, K.M., 2002. We don't train in vain: a randomized trial of three strategies for training clinicians in CBT, (under review).
103. Silverman K., Wong C.J., Umbricht-Schneiter A., Montoya I.D., Schuster C.R., Preston K.L. Broad beneficial effects of cocaine abstinence reinforcement among methadone patients. J. Consult. Clin. Psychol. 66:1998;811-824
104. Sofuoglu, M., Gonzalez, G., Poling, J., Kosten, T.R., 2002. Prediction of treatment outcome by baseline urine cocaine results and self-reported cocaine use for cocaine and opioid dependence, (under review).
105. Stanton M.D., Shadish W.R. Outcome, attrition, and family-couples treatment for drug abuse: a meta-analysis and review of the controlled, comparative studies. Psychol. Bull. 122:1997;170-191
106. Stitzer M.L., Bickel W.K., Bigelow G.E., Liebson I.A. Effect of methadone dose contingencies on urinalysis test results of polydrug abusing methadone maintenance patients. Drug Alcohol Depend. 18:1986;341-348
107. Stitzer M.L., Iguchi M.Y., Felch L.J. Contingent take-home incentives: effects on drug use of methadone maintenance patients. J. Consult. Clin. Psychol. 60:1992;927-934
108. Street L.L., Luoma J.B. Control groups in psychosocial intervention research: Ethical and methodological issues. Ethics Behav. 12:2002;1-30
109. Swift R.M., Duncan D., Nirenberg T.D., Femino J. Alcoholic patients' experience and attitudes on pharmacotherapy for alcoholism. J. Addict. Dis. 17:1998;35-47
110. Szapocznik J., Perez-Vidal A., Brickman A.L., Foote F.H., Santisteban D.A., Hervis O., Kurtines W.M. Engaging adolescent drug abusers and their families in treatment: A strategic structural systems approach. J. Consult. Clin. Psychol. 56:1988;552-557
111. Volkow N.D., Fowler J.S., Wolf A.P., Schlyer D., Shiue C.Y., Alpert R., Dewey S.L., Logan J., Bendriem B., Christman D. Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am. J. Psychiatry. 147:1990;719-724
112. Volpicelli J.R., Alterman A.I., Hayashida M., O'Brien C.P. Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry. 49:1992;876-880
113. Volpicelli, J.R., Pettinati, H.M., McLellan, A.T., O'Brien, C.P., 2001. Combining medication and psychosocial treatments for addictions: the BRENDA approach, Guilford Press, New York.
114. Wilk A.I., Jensen N.M., Havighurst T.C. Meta-analysis of randomized controlled trials addressing brief interventions in heavy alcohol drinkers. J. Gen. Int. Med. 12:1997;274-283